Petosemtamab (FUT8-KO)

Cat. No.: HY-P99406A Pureza: 99%: Ficha de datos
COA

SDS

FAQs
Technical Support

Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).

Para uso exclusivo en investigación. No vendemos a pacientes.

Tamaño	Stock	Cantidad
1 mg	En stock	Estimated Time of Arrival: December 31
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
50 mg	Obtener un presupuesto
100 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas EGFR:

Ver todas las isoformas

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn	Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC)^[1]^[2].
Isotype	Human IgG1 kappa
Recommend Isotype Controls	Human IgG1 kappa, Isotype Control
Species Reactivity	Human
IC₅₀ & Target	GPR49 & LGR5
In Vitro	Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out^[1]^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Petosemtamab (FUT8-KO) Related Antibodies
Gene ID	8549 [NCBI] & 8549 [NCBI]
Accession	O75473 & O75473
Application	ELISA, FACS, Functional assay
Conjugated	Unconjugated
Reconsititution	The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular	145.5 kDa
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Petosemtamab (FUT8-KO)]
Envío	Shipping with dry ice.
Formulation	Please refer to the lot-specific COA for specific buffer information.
Almacenamiento	Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity	Loaded Petosemtamab (FUT8-KO) on ProA biosensor, can bind EGFR Protein, Human (621a.a, CHO, His, HY-P7340) with an affinity constant of 5.043E-09 M as determined in BLI assay.
Pureza y Documentación	Purity: 99% Select Batch: Ficha de datos (257 KB) SDS (251 KB) COA (232 KB) SDS-PAGE (79 KB) SEC-HPLC (291 KB) Inhibitory Antibodies User Guide (603 KB)
Referencias	[1]. Hollebecque A, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma[J]. Molecular Cancer Therapeutics, 2021, 20(12_Supplement): P185-P185. [2]. Argiles G. Phase I dose escalation study of MCLA-158, a first in class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)[J]. chemotherapy, 2021, 33: 100.